BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30969847)

  • 1. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.
    Bohlius J; Bohlke K; Castelli R; Djulbegovic B; Lustberg MB; Martino M; Mountzios G; Peswani N; Porter L; Tanaka TN; Trifirò G; Yang H; Lazo-Langner A
    J Clin Oncol; 2019 May; 37(15):1336-1351. PubMed ID: 30969847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update.
    Bohlius J; Bohlke K; Castelli R; Djulbegovic B; Lustberg MB; Martino M; Mountzios G; Peswani N; Porter L; Tanaka TN; Trifirò G; Yang H; Lazo-Langner A
    Blood Adv; 2019 Apr; 3(8):1197-1210. PubMed ID: 30971397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update.
    Rizzo JD; Somerfield MR; Hagerty KL; Seidenfeld J; Bohlius J; Bennett CL; Cella DF; Djulbegovic B; Goode MJ; Jakubowski AA; Rarick MU; Regan DH; Lichtin AE
    Blood; 2008 Jan; 111(1):25-41. PubMed ID: 17954703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.
    Rizzo JD; Somerfield MR; Hagerty KL; Seidenfeld J; Bohlius J; Bennett CL; Cella DF; Djulbegovic B; Goode MJ; Jakubowski AA; Rarick MU; Regan DH; Lichtin AE; ;
    J Clin Oncol; 2008 Jan; 26(1):132-49. PubMed ID: 17954713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.
    Rizzo JD; Brouwers M; Hurley P; Seidenfeld J; Arcasoy MO; Spivak JL; Bennett CL; Bohlius J; Evanchuk D; Goode MJ; Jakubowski AA; Regan DH; Somerfield MR;
    Blood; 2010 Nov; 116(20):4045-59. PubMed ID: 20974674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.
    Rizzo JD; Brouwers M; Hurley P; Seidenfeld J; Arcasoy MO; Spivak JL; Bennett CL; Bohlius J; Evanchuk D; Goode MJ; Jakubowski AA; Regan DH; Somerfield MR; ;
    J Clin Oncol; 2010 Nov; 28(33):4996-5010. PubMed ID: 20975064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies, and cancer: perspectives with opinion and commentary.
    Musio F
    Expert Rev Hematol; 2020 Nov; 13(11):1175-1188. PubMed ID: 33028115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data.
    Bohlius J; Tonia T; Nüesch E; Jüni P; Fey MF; Egger M; Bernhard J
    Br J Cancer; 2014 Jul; 111(1):33-45. PubMed ID: 24743705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of chemotherapy-induced anemia].
    Kadokura G; Katsumata N
    Gan To Kagaku Ryoho; 2014 Apr; 41(4):416-20. PubMed ID: 24743356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines.
    Djulbegovic B
    Best Pract Res Clin Haematol; 2005; 18(3):455-66. PubMed ID: 15792920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis.
    Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
    BioDrugs; 2019 Aug; 33(4):373-389. PubMed ID: 31161461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy.
    Trotta F; Belleudi V; Fusco D; Amato L; Mecozzi A; Mayer F; Sansone M; Davoli M; Addis A
    BMJ Open; 2017 Mar; 7(3):e011637. PubMed ID: 28283484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis.
    Thadhani R; Guilatco R; Hymes J; Maddux FW; Ahuja A
    Am J Nephrol; 2018; 48(3):214-224. PubMed ID: 30196301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
    Aapro M; Spivak JL
    Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
    Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
    Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epoetin alfa-epbx: a new entrant into a crowded market. a historical review of the role of erythropoietin stimulating agents and the development of the first epoetin biosimilar in the United States.
    Anand S; Al-Mondhiry J; Fischer K; Glaspy J
    Expert Rev Clin Pharmacol; 2021 Jan; 14(1):1-8. PubMed ID: 33307871
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of erythropoiesis-stimulating agents on red blood cell transfusion in Korea.
    Kang RY; Lee J; Lee YH; Lee HS; Jeong JH; Lee YJ
    Int J Clin Pharm; 2012 Aug; 34(4):651-7. PubMed ID: 22729393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey.
    Cortinovis D; Beretta G; Piazza E; Luchena G; Aglione S; Bertolini A; Buzzoni R; Cabiddu M; Carnaghi C; Danova M; Farina G; Ferrari V; Frascaroli M; Reni M; Tansini G;
    Tumori; 2013; 99(1):45-50. PubMed ID: 23548999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.